EX-99.1 2 rdy0800_ex99-1.htm EXHIBIT 99.1

 

Exhibit 99.1

 

Dr. Reddy's Laboratories Ltd.

8-2-337, Road No. 3, Banjara Hills

Hyderabad – 500 034, Telangana, India

 

CIN: L85195TG1984PLC004507

 

Tel:       + 91 40 4900 2900

Fax:      + 91 40 4900 2999

Email:   mail@drreddys.com

Web:      www.drreddys.com

 

September 6, 2025

 

National Stock Exchange of India Ltd. (Scrip Code: DRREDDY)

BSE Limited (Scrip Code: 500124)

New York Stock Exchange Inc. (Stock Code: RDY)

NSE IFSC Ltd. (Stock Code: DRREDDY)

 

Dear Sir/Madam,

 

Ref:

Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

 

This is to inform you that the United States Food & Drug Administration (USFDA) completed a GMP inspection at our API Mirfield facility in West Yorkshire, UK. The inspection was conducted from  September 1 to September 5, 2025. We have been issued a Form 483 with 7 observations, which we will address within the stipulated timeline.

 

This is for your information and record.

 

Thanking you.

 

Yours faithfully,

 

For Dr. Reddy’s Laboratories Limited


K Randhir Singh

Company Secretary, Compliance Officer & Head-CSR